PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer

Molecule-targeted therapy has achieved great progress in cancer therapy. Effective drug combinations are one way to enhance the therapeutic efficacy and combat resistance. Here, we determined the effect of the PI3K/mTOR dual inhibitor BEZ235 and the histone deacetylase inhibitor Trichostatin A (TSA)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Chen, Liyan, Jin, Tiefeng, Zhu, Kun, Piao, Yingshi, Quan, Taihao, Quan, Chunji, Lin, Zhenhua
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355316/
https://ncbi.nlm.nih.gov/pubmed/28060760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14442
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares